Huai C Pan, MD in Fairfield, OH - Plastic Surgery

Huai C Pan, MD is a Plastic Surgery physician based in Fairfield, Ohio. Huai C Pan is licensed to practice in Ohio (license number 41823) and his current practice location is 2960 Mack Rd, Suite 212, Fairfield, Ohio. He can be reached at his office (for appointments etc.) via phone at (513) 874-0808.

NPI number for Huai C Pan is 1124098215 and his current mailing address is 2960 Mack Rd, Suite 212, Fairfield, Ohio. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1124098215.

Contact Information

	Huai C Pan, MD
	2960 Mack Rd, Suite 212, Fairfield, OH 45014-5373
	(513) 874-0808
	Not Available

Physician's Profile

Full Name	Huai C Pan
Gender	Male
Speciality	Plastic Surgery
Location	2960 Mack Rd, Fairfield, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1124098215
Provider Enumeration Date: 01/23/2006
Last Update Date: 12/26/2007

Medical Identifiers

Medical identifiers for Huai C Pan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1124098215	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	41823 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Huai C Pan is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Huai C Pan, MD 2960 Mack Rd, Suite 212, Fairfield, OH 45014-5373 Ph: (513) 874-0808	Huai C Pan, MD 2960 Mack Rd, Suite 212, Fairfield, OH 45014-5373 Ph: (513) 874-0808

News Archive

Biomagnetics signs LOI to acquire Lanzhou Sanhuan New Technology Development

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. This expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for Biomagnetics Diagnostics' common shares.

Neoadjuvant trial of combination immunotherapy has favorable outcomes in bladder cancer patients

Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.

Lab21 acquires molecular diagnostics company Myconostica Ltd

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has today announced that it has acquired Myconostica Ltd, a molecular diagnostic company focussing on the diagnosis of fungal infections of clinical importance.

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

Huai C Pan, MD - Plastic Surgery in Fairfield, OH